Drugs / beta-tricalcium phosphate
beta-tricalcium phosphate
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04620252 | Feb 2021 → Mar 2022 | dental caries | University of Michigan | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT06935747 | Jul 2025 → Mar 2026 overdue | bone resorption disease, impacted teeth, multiple | Mario Pérez Sayáns | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT02507661 | Jun 2015 → Jan 2018 | — | University of Belgrade | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04124887 | Feb 2017 → Feb 2018 | tooth resorption | Kırıkkale University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02795546 Background | Jan 2015 → Apr 2016 | periodontal disorder | Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | beta-tricalcium phosphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02795546 ↗ |
| Known as | BTCP | “The proposed protocol is a multicenter clinical trial aimed at analyzing the osteogenic action of a medical device based on beta-tricalcium phosphate (hereinafter BTCP) in the...” NCT06935747 ↗ |
| Known as | tricalcium phosphate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04620252 ↗ |
| Modality | Other / unclassified | “medical device” NCT06935747 ↗ |
| Route | Other | “beta-tricalcium phosphate bone graft is implanted in periodontal intra-osseous defects.” NCT02795546 ↗ |